A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
NCT ID: NCT00456053
Last Updated: 2007-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
145 participants
INTERVENTIONAL
2005-12-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FG2216
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* appropriate hemoglobin levels
Exclusion Criteria
* Macular edema or proliferative retinopathy in diabetic subjects, requiring treatment
* Any history of malignancy
* Therapy with recombinant erythropoietin or red blood cell transfusion within 4 weeks
* Renal Transplant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FibroGen
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Tucson, Arizona, United States
Research Site
Little Rock, Arkansas, United States
3 Research Sites
Los Angeles, California, United States
Research Site
Oakland, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Clara, California, United States
Research Site
Lauderdale Lakes, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Pembroke Pines, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
South Holland, Illinois, United States
Research Site
Shreveport, Louisiana, United States
Research Site
Springfield, Massachusetts, United States
Research Site
Kalamazoo, Michigan, United States
Research Site
Pontiac, Michigan, United States
Research Site
Flushing, New York, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Portland, Oregon, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Hershey, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Orangeburg, South Carolina, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Chesapeake, Virginia, United States
Research Site
Fairfax, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FGCL-SM2216-019
Identifier Type: -
Identifier Source: org_study_id